Free Trial

Amylyx Pharmaceuticals Q1 2023 Earnings Report

Amylyx Pharmaceuticals logo
$3.67 -0.24 (-6.14%)
As of 04:00 PM Eastern

Amylyx Pharmaceuticals EPS Results

Actual EPS
$0.02
Consensus EPS
-$0.27
Beat/Miss
Beat by +$0.29
One Year Ago EPS
N/A

Amylyx Pharmaceuticals Revenue Results

Actual Revenue
$71.43 million
Expected Revenue
$57.35 million
Beat/Miss
Beat by +$14.08 million
YoY Revenue Growth
N/A

Amylyx Pharmaceuticals Announcement Details

Quarter
Q1 2023
Time
N/A

Conference Call Resources

Conference Call Audio

Remove Ads

Amylyx Pharmaceuticals Earnings Headlines

HC Wainwright Issues Pessimistic Outlook for AMLX Earnings
Research Analysts Issue Forecasts for AMLX Q1 Earnings
Collect $7k per month from Tesla’s SECRET dividend
Tesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69% dividend from Tesla… Which could put up to $7,013 in your pocket every month…
See More Amylyx Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Amylyx Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Amylyx Pharmaceuticals and other key companies, straight to your email.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals (NASDAQ:AMLX), a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

View Amylyx Pharmaceuticals Profile

More Earnings Resources from MarketBeat